Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

An early study with gemcitabine in pancreas cancer indicated greater relief of disease-related symptoms than expected from the objective tumour response rate. A novel design was created to assess changes in symptomatology prospectively in two studies. The design focuses on typical features seen in patients with advanced pancreas cancer (pain, impaired function, weight loss) and the endpoint is 'clinical benefit response'. Traditional endpoints of objective tumour response and survival were also included. In a randomised study, the clnical benefit response rate for gemcitabine was 24% compared with 5% for 5-fluorouracil (5-FU) (P = 0.0022). The median survival was 5.65 months for gemcitabine compared with 4.41 months for 5-FU (P = 0.0025). The corresponding objective response rates were 5.4% and 0%. Disease stabilised in 39% and 19% of gemcitabine and 5-FU patients, respectively. In a second study of 5-FU-refractory patients, 27.0% of patients were clinical benefit responders. The median survival in this second study was 3.8 months; the objective response rate was 11%, and 30% of patients had stable disease, These trials show that gemcitabine improves disease-related symptoms and survival in patients with pancreas cancer.

Original languageEnglish (US)
JournalEuropean Journal of Cancer
Volume33
Issue numberSUPPL. 1
StatePublished - Jan 1997

Fingerprint

gemcitabine
Pancreatic Neoplasms
Fluorouracil
Survival
Therapeutics
Weight Loss
Neoplasms

Keywords

  • Chemotherapy
  • Clinical benefit
  • Clinical trial
  • Gemcitabine
  • Pancreas cancer
  • Quality of life
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Assessing clinical benefit in the treatment of pancreas cancer : Gemcitabine compared to 5-fluorouracil. / Burris, H.; Storniolo, Anna Maria.

In: European Journal of Cancer, Vol. 33, No. SUPPL. 1, 01.1997.

Research output: Contribution to journalArticle

@article{7f6a8547a85a40ea8893aae5570ae99d,
title = "Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil",
abstract = "An early study with gemcitabine in pancreas cancer indicated greater relief of disease-related symptoms than expected from the objective tumour response rate. A novel design was created to assess changes in symptomatology prospectively in two studies. The design focuses on typical features seen in patients with advanced pancreas cancer (pain, impaired function, weight loss) and the endpoint is 'clinical benefit response'. Traditional endpoints of objective tumour response and survival were also included. In a randomised study, the clnical benefit response rate for gemcitabine was 24{\%} compared with 5{\%} for 5-fluorouracil (5-FU) (P = 0.0022). The median survival was 5.65 months for gemcitabine compared with 4.41 months for 5-FU (P = 0.0025). The corresponding objective response rates were 5.4{\%} and 0{\%}. Disease stabilised in 39{\%} and 19{\%} of gemcitabine and 5-FU patients, respectively. In a second study of 5-FU-refractory patients, 27.0{\%} of patients were clinical benefit responders. The median survival in this second study was 3.8 months; the objective response rate was 11{\%}, and 30{\%} of patients had stable disease, These trials show that gemcitabine improves disease-related symptoms and survival in patients with pancreas cancer.",
keywords = "Chemotherapy, Clinical benefit, Clinical trial, Gemcitabine, Pancreas cancer, Quality of life, Review",
author = "H. Burris and Storniolo, {Anna Maria}",
year = "1997",
month = "1",
language = "English (US)",
volume = "33",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Assessing clinical benefit in the treatment of pancreas cancer

T2 - Gemcitabine compared to 5-fluorouracil

AU - Burris, H.

AU - Storniolo, Anna Maria

PY - 1997/1

Y1 - 1997/1

N2 - An early study with gemcitabine in pancreas cancer indicated greater relief of disease-related symptoms than expected from the objective tumour response rate. A novel design was created to assess changes in symptomatology prospectively in two studies. The design focuses on typical features seen in patients with advanced pancreas cancer (pain, impaired function, weight loss) and the endpoint is 'clinical benefit response'. Traditional endpoints of objective tumour response and survival were also included. In a randomised study, the clnical benefit response rate for gemcitabine was 24% compared with 5% for 5-fluorouracil (5-FU) (P = 0.0022). The median survival was 5.65 months for gemcitabine compared with 4.41 months for 5-FU (P = 0.0025). The corresponding objective response rates were 5.4% and 0%. Disease stabilised in 39% and 19% of gemcitabine and 5-FU patients, respectively. In a second study of 5-FU-refractory patients, 27.0% of patients were clinical benefit responders. The median survival in this second study was 3.8 months; the objective response rate was 11%, and 30% of patients had stable disease, These trials show that gemcitabine improves disease-related symptoms and survival in patients with pancreas cancer.

AB - An early study with gemcitabine in pancreas cancer indicated greater relief of disease-related symptoms than expected from the objective tumour response rate. A novel design was created to assess changes in symptomatology prospectively in two studies. The design focuses on typical features seen in patients with advanced pancreas cancer (pain, impaired function, weight loss) and the endpoint is 'clinical benefit response'. Traditional endpoints of objective tumour response and survival were also included. In a randomised study, the clnical benefit response rate for gemcitabine was 24% compared with 5% for 5-fluorouracil (5-FU) (P = 0.0022). The median survival was 5.65 months for gemcitabine compared with 4.41 months for 5-FU (P = 0.0025). The corresponding objective response rates were 5.4% and 0%. Disease stabilised in 39% and 19% of gemcitabine and 5-FU patients, respectively. In a second study of 5-FU-refractory patients, 27.0% of patients were clinical benefit responders. The median survival in this second study was 3.8 months; the objective response rate was 11%, and 30% of patients had stable disease, These trials show that gemcitabine improves disease-related symptoms and survival in patients with pancreas cancer.

KW - Chemotherapy

KW - Clinical benefit

KW - Clinical trial

KW - Gemcitabine

KW - Pancreas cancer

KW - Quality of life

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=0030964122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030964122&partnerID=8YFLogxK

M3 - Article

C2 - 9166095

AN - SCOPUS:0030964122

VL - 33

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - SUPPL. 1

ER -